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ABSTRACT 
Objectives: To assess the associations of body mass index (BMI) with modifiable cardiovascular 
disease (CVD) risk factors in patients with rheumatoid arthritis (RA) 
Methods: BMI, disease activity, selected CVD risk factors and CVD medication were assessed in 
378 (276 females) RA patients. Patients exceeding accepted thresholds in ≥3 CVD risk factors 
were classified as having the metabolic syndrome (MetS).  
Results: BMI independently associated with hypertension (OR=1.28 (95% CI=1.22-1.34); 
p=0.001), HDL (OR=1.10 (1.06-1.15); p=0.025), insulin resistance (OR= 1.13 (1.08-1.18); 
p=0.000) and the MetS (OR=1.15 (1.08-1.21); p=0.000). In multivariable analyses, BMI had the 
strongest associations with CVD risk factors (F1-354=8.663, p=0.000), and was followed by lipid-
lowering treatment (F1-354=7.651, p=0.000), age (F1-354=7.541, p=0.000), antihypertensive 
treatment (F1-354=4.997, p=0.000) and gender (F1-354=4.707, p=0.000). Prevalence of hypertension 
(p=0.004), insulin resistance (p=0.005) and the MetS (p=0.000) was significantly different 
between normal, overweight and obese RA patients, and BMI differed significantly according to 
the number of risk factors present (p=0.000). 
Conclusions:  Increasing BMI associates with increased CVD risk independently of many 
confounders. RA-specific BMI cut-off points better identify RA patients at increased CVD risk. 
Weight-loss regimes should be developed and applied in order to reduce CVD in RA patients. 
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INTRODUCTION 
Rheumatoid arthritis (RA) associates with increased risk for cardiovascular disease (CVD) 
[1]. This is most likely a combination of genetic predisposition [2], modifiable CVD risk factors 
and the inflammatory burden of the disease [3]. RA patients have significantly higher body fat 
content compared to healthy individuals of the same height and weight [4]. This led to the 
development of RA-specific body mass index (BMI) thresholds for overweight and obesity that 
better identify RA patients with increased body fat [4], and possibly CVD risk. 
In the general population, obesity is a major contributor to dyslipidaemia, hypertension, 
and insulin resistance [5] and the underlying cause of the metabolic syndrome (MetS) [5]. The 
associations between obesity and CVD risk factors or the MetS in RA have not been extensively 
investigated. Obesity in this population is usually considered a confounder, against which data 
should be standardised, but not as the possible underlying cause for several CVD risk factors. The 
aim of this study was to quantify the associations of BMI with classical CVD risk factors in a large 
sample of RA patients.  
 
METHODS 
Participants 
The study had ethical approval and all volunteers provided informed consent. A total of 
400 (289 female) consecutive RA patients were assessed. Of them none had uncontrolled thyroid 
disease, but 22 were excluded due to cancer. The analyses from the remaining 378 (276 female) 
patients are reported: their characteristics appear in Table 1. 
 
Table 1: Demographic and disease characteristics of volunteers [median (interquartile range)]  
 
 MALE FEMALE 
N 102 276 
Age 63.5 (13.6) 63 (14.8) 
Height 173.0 (9.8) 160.0 (8.0) 
Weight 83.3 (19.7) 70.0 (19.9) 
BMI 27.6 (5.5) 26.7 (7.2) 
DAS28 4.0 (1.8) 4.2 (1.9) 
HAQ 1.2 (1.8) 1.6 (1.5) 
ESR 19.0 (30.0) 21.0 (28.0) 
CRP 10.0 (15.0) 8.0 (13.0) 
Disease Duration 9.0 (15.0) 10.0 (15.0) 
 
 
Assessments 
Standing height, weight, BMI (kg/m2) and waist circumference were measured. CVD risk 
factors (blood pressure [BP], lipids) were assessed, smoking status noted and the Framingham 10-
year CVD event probability was calculated. The Homeostasis Model Assessment of insulin 
resistance (HOMA) and the Quantitative Insulin sensitivity Check Index (QUICKI),were used to 
determine insulin resistance (IR). The NCEP ATP III criteria [5] were used to identify patients 
with the MetS.  Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Disease Activity 
Score-28 (DAS28), and the Stanford Health Assessment Questionnaire (HAQ) were also assessed. 
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Data Analysis 
The Statistical Package for Social Sciences version 15.0 was used (SPSS Inc. Chicago, IL, 
USA). Dispersion of the variables was assessed using the Kolmogorov-Smirnov test. Spearman’s 
correlations explored the associations of CVD risk factors and 10-year CVD event probability with 
BMI. Results were standardised for gender, age, smoking status, RA characteristics and CVD 
medication using univariable analyses. Multivariable analyses were used to asses the overall 
association of each of the possible confounders with the CVD risk factors and the 10-year CVD 
event probability.  
Following grouping according to RA-specific BMI [4] in underweight, normal-weight, 
overweight and obese, analysis of Variance (ANOVA) was used to assess differences in BP, lipids 
and IR between groups. Analysis of Co-Variance (ANCOVA) was then used to standardise for the 
same possible confounders as above. Chi-squared analyses were used to identify differences in the 
prevalence of each risk factor or the MetS between BMI groups. Binary logistic models were used 
to test the independence of these associations from the same possible confounders.  
Finally, patients were grouped according to the total number of risk factors they had. 
ANOVA was used to assess differences in BMI among these latter groups and ANCOVA to adjust 
for the same possible confounders. Data are reported as median (interquartile range). Statistical 
significance was set to p<0.05. 
 
RESULTS 
BMI and CVD risk factors 
BMI correlated significantly with systolic BP (r=0.240, p=0.000), HDL (r=-183, p=0.000), 
HOMA (r=0.302, p=0.000) and QUICKI (r=-0.300, p=0.000). BMI also correlated with ESR 
(r=0.128, p=0.011), CRP (r=0.155, p=0.002) and HAQ (r=0.133, p=0.009), therefore results were 
standardised for these parameters as well as for gender, age, smoking, and CVD medication. BMI 
retained its association with systolic BP (F1-354=23,372, p=0.000), HDL (F1-354=10.439, p=0.001), 
HOMA (F1-354=11.311, p=0.001) and QUICKI (F1-354=34.678, p=0.000) and also associated with 
diastolic BP (F1-354=7,593, p=0.006), triglycerides (F1-354=4.496, p=0.035) and 10-year CVD event 
probability (F1-354=5.857, p=0.016). Different multivariate models, using BP, lipids and IR as 
dependent variables, gender and smoking status as factors and BMI, age, RA characteristics and 
CVD medication as covariates indicated that the variance observed in all CVD risk factors was 
more closely associated with BMI (F1-354=8.663, p=0.000), followed by lipid-lowering treatment 
(F1-354=7.651, p=0.000), age (F1-354=7.541, p=0.000), antihypertensive treatment (F1-354=4.997, 
p=0.000) and male gender (F1-354=4.707, p=0.000).  
 ANCOVA, with corrections for gender, age, smoking, RA characteristics and usage of 
CVD medication, showed significant differences between BMI sub-groups (underweight, normal-
weight, overweight and obese) for systolic BP (F1-354=14.707, p=0.000), diastolic BP (F1-354=6.457, 
p=0.011), triglycerides (F1-354=4.700, p=0.031), HDL (F1-354=7.545, p=006), HOMA (F1-354=9.720, 
p=0.002), QUICKI (F1-354=30.332, p=0.000) and 10-year CVD event probability (F1-354=3.981, 
p=0.046). 
 
BMI subgroups and the prevalence of CVD risk factors 
 Cross-tabulation of BMI subgroups with presence or absence of each risk factor or the 
MetS demonstrated significant differences between groups for the prevalence of hypertension 
(p=0.004), insulin resistance (p=0.005) and the MetS (p=0.000) (Figure 1). The binary logistic 
models indicated that BMI associated with hypertension (OR=1.28, 95% CI=1.22-1.34; p=0.001), 
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HDL (OR=1.10, 95% CI: 1.06-1.15; p=0.025), IR (OR=1.13, 95% CI=1.08-1.18; p=0.000) and the 
MetS (OR=1.15, 95% CI: 1.08-1.21; p=0.000) independently of confounding factors. 
 Following grouping for the total number of risk factors present, ANOVA showed 
significant differences in BMI between groups (p=0.000; Table 1), while ANCOVA revealed that 
this association was independent of gender, age, smoking, RA characteristics and usage of CVD 
medication (p=0.000).  
  
DISCUSSION 
These results suggest an almost linear relationship between BMI and CVD risk in this 
patient group, with the risk profile worsening as BMI increases, in a pattern similar to that 
described in the general population [5]. These associations were independent of multiple 
confounders, and if anything, they became stronger following inclusion of CVD medication in the 
models. It must be emphasised that these are all cross-sectional associations, and they do not 
provide definitive evidence for causality or directionality: longitudinal studies are required for this.  
There is no reason to suggest that the mechanisms by which obesity increases CVD risk in 
RA are different from those in the general population. Excess adipose tissue releases nonesterified 
fatty acids in the circulation, which overload the liver and muscles with lipids and increase 
lipolysis, while reducing glucose utilization. Circulating glucose stimulates insulin production, 
leading to insulin resistance [6]. Endothelial function is often impaired causing arterial stiffness 
and hypertension [7]. Obesity may also increase CVD risk by reducing adiponectin, activating the 
rennin-angiotensin-aldosterone system, and increasing sympathetic activity and renal sodium 
reabsorption [6]. However as we did not measure any of these parameters we can only postulate 
about their contribution to our observations.  
Recent studies in RA have shown no relation [8] or even a “paradoxical” protective effect 
of obesity against CVD [9], although no potential mechanisms were described. In our study, lipid-
lowering and anti-hypertensive drugs strongly associated with CVD risk factors; their inclusion in 
the models strengthened the association of BMI with all risk factors assessed. Such drugs, known 
to improve CVD risk and reduce mortality, are more frequently prescribed in obese than in non-
obese individuals [10]. Thus their inclusion in the analyses of studies investigating CVD risk and 
outcome in RA is of paramount importance.  
In the present study, neither disease characteristics nor smoking affected the associations of 
BMI with CVD risk. This finding is similar to our previous observations indicating that alterations 
in body composition of RA patients occur in the early years of the disease [4] or even prior to it. 
This could be the case for some CVD risk factors since “the risk of coronary heart disease in RA 
patients precedes the ACR criteria-based diagnosis of RA” [11]. Similarly, smoking appears to 
confer less CVD risk in RA than in the general population [3]. Most likely, this is a result of the 
smoking-induced weight-loss we recently described in RA [12] which may counteract the known 
negative effects of smoking on risk factors. However, disease characteristics and smoking were 
treated solely as possible confounders, thus their direct associations with CVD risk in RA cannot 
be assessed in this study. 
An important finding of the present study is the BMI level at which CVD risk increases.  
Patients with one risk factor had a median BMI of <25kg/m2 whereas those with the MetS <30 
kg/m2 and by applying general BMI thresholds would be classified as normal-weight and 
overweight respectively; however, based on RA-specific BMI thresholds they would be classified 
as over-weight or obese. This could be important in routine clinical practice, where such 
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classifications may be used to target patients at increased risk for screening, early identification 
and management of risk factors. 
In the general population, weight-loss can reverse the adverse effects of obesity. However, 
in a population with significant muscle wasting, such as RA, the type of weight-loss intervention 
has to be carefully considered. Among existing weight-loss regimes, exercise and especially 
resistance training, is the only one proven to increase muscle mass in the general population [13] 
and may be applied in RA patients without aggravating their disease [14]. Moreover, exercise is 
known to further reduce CVD risk irrespective of weight-loss [15]. Research focusing on weight-
loss interventions and their effects on CVD in RA are necessary.  
Within its limitations, this study shows that increasing BMI in RA patients associates with 
increased CVD risk. The use of RA-specific BMI thresholds better identifies RA patients at 
increased CVD risk. Weight-loss regimes specific for RA patients need to be developed and 
evaluated. 
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LIST OF ABBREVIATIONS 
RA: Rheumatoid Arthritis 
BMI: Body Mass Index 
CVD: Cardiovascular Disease 
HDL: High Density Lipoprotein 
LDL: Low Density Lipoprotein 
BP: Blood Pressure 
IR: Insulin Resistance 
HOMA: Homeostasis Model Assessment of Insulin Resistance 
QUICKI: Quantitative Insulin sensitivity Check Index 
MetS: Metabolic Syndrome 
ESR: Erythrocyte Sedimentation Rate 
CRP: C- Reactive Protein  
DAS: Disease Activity Score 28 
HAQ: Health Assessment Questionnaire 
ANOVA: Analysis of Variance 
ANCOVA: Analysis of Co-variance 
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FIGURE LEGENDS 
 
Figure 1: Mean (95% confidence interval of the mean) for BMI of participants according to risk 
factor grouping. 
 
Differences between groups in BMI are significant (p=0.000) 
Risk factors include: Hypertension, high triglycerides, low high-density-lipoprotein, insulin 
resistance, waist circumference 
 
Figure 2: Prevalence of individual risk factors and the metabolic syndrome for each BMI group 
 
Significant differences between BMI groups were found for the prevalence of hypertension 
(p=0.004), insulin resistance (p=0.005) and the metabolic syndrome (p=0.000).
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